3,4-methylenedioxyamphetamine has been researched along with Nervous System Disorders in 23 studies
3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For future research, challenge studies in animals using dosing regimens adapted to human consumption patterns are needed." | 2.42 | The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). ( Freudenmann, RW; Spitzer, M, 2004) |
| " Perhaps as a consequence of this, the toxic effects of MDMA in the monkey involve serotonergic nerve fibers as well as cell bodies, whereas in the rat, only nerve fibers are affected." | 2.38 | Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans. ( Ricaurte, GA, 1989) |
| "Regulation of neurotoxicants is generally based on setting allowable doses (exposures) by dividing a no observed adverse effect level (NOAEL) by uncertainty factors that hopefully account for interspecies and intraspecies differences for extrapolations of experimental results obtained in animals to humans." | 1.28 | Risk assessment for neurotoxic effects. ( Gaylor, DW; Slikker, W, 1990) |
| " However, a comparison of the relative toxic effects of MDMA and MBDB indicates that MBDB may be slightly less neurotoxic." | 1.28 | Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. ( Johnson, MP; Nichols, DE, 1989) |
| " The central monoamine stores of rats were significantly decreased with reserpine (5 mg/kg) prior to toxic injections of MDMA." | 1.28 | Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat. ( Hekmatpanah, CR; McKenna, DJ; Peroutka, SJ, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (34.78) | 18.7374 |
| 1990's | 14 (60.87) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freudenmann, RW | 1 |
| Spitzer, M | 1 |
| Brodkin, J | 1 |
| Malyala, A | 1 |
| Nash, JF | 1 |
| Merrill, J | 1 |
| Saunders, N | 1 |
| Winstock, AR | 1 |
| King, LA | 1 |
| Grob, CS | 1 |
| Bravo, GL | 1 |
| Walsh, RN | 1 |
| Liester, MB | 1 |
| Steele, TD | 2 |
| Katz, JL | 1 |
| Ricaurte, GA | 2 |
| Brewster, WK | 1 |
| Johnson, MP | 2 |
| Nichols, DE | 2 |
| Yim, GK | 1 |
| Schmidt, CJ | 3 |
| Black, CK | 2 |
| Taylor, VL | 2 |
| Gaylor, DW | 1 |
| Slikker, W | 1 |
| Paris, JM | 1 |
| Cunningham, KA | 1 |
| Markert, LE | 1 |
| Roberts, DC | 1 |
| Grob, C | 1 |
| Bravo, G | 1 |
| Walsh, R | 1 |
| Gibb, JW | 2 |
| Johnson, M | 2 |
| Hanson, GR | 2 |
| Stone, DM | 1 |
| Bush, LG | 1 |
| Peroutka, SJ | 2 |
| Hekmatpanah, CR | 1 |
| McKenna, DJ | 1 |
| Barnes, DM | 1 |
| Logan, BJ | 1 |
| Laverty, R | 1 |
| Sanderson, WD | 1 |
| Yee, YB | 1 |
3 reviews available for 3,4-methylenedioxyamphetamine and Nervous System Disorders
| Article | Year |
|---|---|
The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA).
Topics: 3,4-Methylenedioxyamphetamine; Animals; Drug Administration Schedule; Drug Interactions; Europe; Hal | 2004 |
Acute and long-term neurochemical effects of methylenedioxymethamphetamine in the rat.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain Chemistry; N-Methyl-3,4-methylenedioxyam | 1989 |
Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Humans; N-Methyl-3,4-methylenedioxyamphetamine | 1989 |
1 trial available for 3,4-methylenedioxyamphetamine and Nervous System Disorders
| Article | Year |
|---|---|
Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Clinical Trials as Topic; Designer Drugs; Huma | 1990 |
19 other studies available for 3,4-methylenedioxyamphetamine and Nervous System Disorders
| Article | Year |
|---|---|
Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; alpha-Methyltyrosine; Animals; Axons; Biogenic Monoamines; Brain Chem | 1993 |
Ecstasy and neurodegeneration. Advice is that "less is more".
Topics: 3,4-Methylenedioxyamphetamine; Chronic Disease; Designer Drugs; Humans; Nervous System Diseases; Ris | 1996 |
Ecstasy and neurodegeneration. No evidence of neurotoxicity exists.
Topics: 3,4-Methylenedioxyamphetamine; Brain Diseases; Chronic Disease; Designer Drugs; Humans; Nervous Syst | 1996 |
Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy...
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Drug Contamination; Humans; Nervous System Diseases; | 1996 |
The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Combined Modality Therapy; Designer Drugs; Humans; Mental Di | 1992 |
Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA).
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain Chemistry; Hallucinogens; Hydroxyindolea | 1992 |
Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Biogenic Amines; Brain Chemistry; Chromatography, High Press | 1991 |
L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; | 1991 |
Risk assessment for neurotoxic effects.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Axons; Designer Drugs; Female; Hippocampus; Hydroxyindoleace | 1990 |
Lack of neurotoxicity after intra-raphe micro-injections of MDMA ("ecstasy").
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Catecholamines; Chromatography, High Pressu | 1990 |
3,4-Methylenedioxyamphetamine (MDA) self-administration and neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Biogenic Monoamines; Brain Chemistry; Chromatography, High P | 1991 |
Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; | 1990 |
Neurochemical basis of neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Biogenic Monoamines; Designer Drugs; Dopamine; Glutamates; M | 1990 |
Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Adrenalectomy; Amphetamines; Animals; Cerebral Cortex; Corticosterone | 1989 |
Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Biogenic Monoamines; Brain Chemistry; Hydroxyi | 1989 |
'Ecstasy': a human neurotoxin?
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Nervous | 1989 |
Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Cerebral Cortex; Corpus Striatum; Designer Dru | 1989 |
New data intensify the agony over ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain; Haplorhini; Humans; Legislation, Drug; | 1988 |
Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Biogenic Monoamines; Dopamine; Male; Methoxyhy | 1988 |